{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:02:28Z","timestamp":1787065348681,"version":"build-2736575974"},"reference-count":35,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PROM"],"DOI":"10.2147\/prom.s411721","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:20:09Z","timestamp":1688689209000},"page":"213-222","source":"Crossref","is-referenced-by-count":9,"title":["The Transthyretin Amyloidosis \u2013 Quality of Life (ATTR-QOL) Questionnaire: Development of a Conceptual Model and Disease-Specific Patient-Reported Outcome Measure"],"prefix":"10.1080","volume":"Volume 14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-2952","authenticated-orcid":true,"given":"Meaghan","family":"O'Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-9877","authenticated-orcid":true,"given":"Lynne","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen L","family":"McCausland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"LaGasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rebello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Carty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7]]},"reference":[{"key":"ref1","unstructured":"Cleveland Clinic. Amyloidosis: ATTR; 2019. Available from: https:\/\/my.clevelandclinic.org\/health\/diseases\/17855-amyloidosis-attr. Accessed October 04, 2019."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref4","unstructured":"Coelho T, Ericzon FR, et al. A guide to transthyretin amyloidosis; 2016."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14797\/mdcvj.1066","volume":"18","author":"Obi","year":"2022","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"949401","DOI":"10.3389\/fneur.2022.949401","volume":"13","author":"Shije","year":"2022","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/genes12070955","author":"Minnella","year":"2021","journal-title":"Genes"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1212\/WNL.0000000000012965","volume":"97","author":"Sousa","year":"2021","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00401-022-02501-9","volume":"145","author":"Taipa","year":"2023","journal-title":"Acta Neuropathol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"ref14","first-page":"S107","volume":"23","author":"Gertz","year":"2017","journal-title":"Am J Manag Care"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"Wixner","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"A436","DOI":"10.1016\/j.jval.2016.09.518","volume":"19","author":"Denoncourt","year":"2016","journal-title":"Value Health"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.cardfail.2017.07.298","volume":"23","author":"Grogan","year":"2017","journal-title":"J Card Fail"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"A386","DOI":"10.1016\/j.jval.2013.08.365","volume":"16","author":"Stewart","year":"2013","journal-title":"Value Health"},{"key":"ref20","unstructured":"Amyloidosis research consortium advancing amyloidosis: a research roadmap. Available from: https:\/\/www.arci.org\/wp-content\/uploads\/2019\/03\/ARC-White-Paper-Final-v3.pdf. Accessed September 06, 2019."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e13598","DOI":"10.1111\/eci.13598","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/PROM.S264034","volume":"11","author":"Rizio","year":"2020","journal-title":"Patient Relat Outcome Meas"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"ref24","unstructured":"Terwee CB, Prinsen CA, Chiarotto A, et al. COSMIN methodology for assessing the content validity of PROMs: user manual, version 1.0; 2018."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11136-020-02625-z","volume":"30","author":"Crossnohere","year":"2021","journal-title":"Qual Life Res"},{"key":"ref26","volume-title":"Cognitive Interviewing","year":"2005"},{"key":"ref27","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input: guidance for industry, food and drug administration staff, and other stakeholders; 2020. Available from: https:\/\/www.fda.gov\/media\/139088\/download. Accessed July 12, 2021."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"160940691770298","DOI":"10.1177\/1609406917702983","volume":"16","author":"Cheng","year":"2017","journal-title":"Int J Qual Methods"},{"key":"ref30","unstructured":"US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims; 2009. Available from: https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf.%20Updated%20March%2023,%202017. Accessed March 25, 2019."},{"key":"ref31","unstructured":"US Food and Drug Administration. Patient-focused drug development guidance public workshop: methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments; 2018. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/NewsEvents\/UCM620708.pdf. Accessed March 25, 2019."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.1931099","author":"Damy","year":"2021","journal-title":"Amyloid"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/jns.12403","volume":"25","author":"Wajnsztajn Yungher","year":"2020","journal-title":"J Peripher Nerv Syst"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"644508","DOI":"10.3389\/fcvm.2021.644508","volume":"8","author":"Sabbour","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"ref35","unstructured":"O\u2019Connor M, Broderick L, Brown D, et al. Comparison of symptoms experienced by patients with ATTRwt and hATTR: findings from the development of an ATTR-specific PRO. Presentation at Presented at the 2021 3rd European ATTR Amyloidosis Meeting for Patients and Doctors, September 6\u20138; 2021."}],"container-title":["Patient Related Outcome Measures"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=91008","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=91008","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:25:17Z","timestamp":1780352717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/the-transthyretin-amyloidosis--quality-of-life-attr-qol-questionnaire--peer-reviewed-fulltext-article-PROM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2147\/prom.s411721","relation":{},"ISSN":["1179-271X"],"issn-type":[{"value":"1179-271X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}